BNP/PUT/ELI LILLY & CO/900/0.1/20.09.24 | Real-time Boerse Frankfurt Warrants 05:20:57 2024-06-27 EDT | ||
| 4.1 EUR | -6.39% |
|
| Current month | -53.05% | ||
| 1 month | -55.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 4.1 | -6.39% |
| 24-06-26 | 4.38 | +1.62% |
| 24-06-25 | 4.31 | -7.31% |
| 24-06-24 | 4.65 | -11.26% |
| 24-06-21 | 5.24 | -2.06% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 05:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC7ZJA |
| ISIN | DE000PC7ZJA1 |
| Date issued | 2024-04-09 |
| Strike | 900 $ |
| Maturity | 2024-09-20 (86 Days) |
| Parity | 10 : 1 |
| Emission price | 12.4 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.33 € |
|---|---|
| Lowest since issue | 3.92 € |
| Spread | 0.03 € |
| Spread % | 0.71% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
